Subscribe to Science Friday
A new mRNA vaccine for melanoma is making headlines. Moderna and Merck recently announced results from their clinical trial suggesting that this new vaccine, in combination with the cancer drug Keytruda, reduced recurrence rates in patients. The companies have not yet released full data from the trial.
So, how does the vaccine work? And does this mark the beginning of a new era of cancer treatments using mRNA vaccine technology? Ira talks with physician Michael Postow, whose patients were part of the drug trial at Memorial Sloan Kettering Cancer Center.
Donate To Science Friday
Invest in quality science journalism by making a donation to Science Friday.
Segment Guests
Michael Postow
Dr. Michael Postow is chief of the melanoma service at Memorial Sloan Kettering Cancer Center.
Segment Transcript
The transcript is being processed. It will be available 2-3 days after this story’s publication date.
Meet the Producers and Host
About Ira Flatow
Ira Flatow is the founder and host of Science Friday. His green thumb has revived many an office plant at death’s door.
About Shoshannah Buxbaum
Shoshannah Buxbaum is a producer for Science Friday. She’s particularly drawn to stories about health, psychology, and the environment. She’s a proud New Jersey native and will happily share her opinions on why the state is deserving of a little more love.